“In the investing blog, I seek to help you take sound investment decisions free from emotion by sharing my
objective insights on markets, sectors, and companies.”
Sam Subramanian PhD, MBA, Editor, AlphaProfit MoneyMatters
July has been a good month for biotech investors. Share prices in the biotech sector as measured by the NYSE Biotechnology Index are up 24% compared to the 6.6% gain for the S&P 500. Earlier in the month, Amgen (AMGN) reported better-than-expected results from a trial of its experimental bone-protecting drug denosumab in patients with advanced breast cancer.… Read More »
Biotechnology, which has been on a roll, declined after the much-anticipated American Society of Clinical Oncologists meeting in early June in New Orleans, where cancer specialists deliberated on the merits of new treatments. The two extant ETFs which focus on this industry are iShares Nasdaq Biotechnology (AMEX:IBB) and Biotech HOLDRs (AMEX:BBH). Before deciding to dump or load up… Read More »
Investing in biotech stocks has never been for the faint-hearted as many biotech companies have high cash burn rates. The biotech industry however has a few things going for it. Read on to learn more about investment opportunities in this industry. Shares of biotechnology companies have declined, after the much anticipated American Society of Clinical Oncologists meeting in… Read More »
The favorable dynamics for the Biotechnology industry is attracting investor attention. On the heels of recent gains, there are reasons to be optimistic on continued out-performance. An efficient Food and Drug Administration, progress on extension of new products, trouble in ‘major pharma’ land and reasonable valuation create a favorable milieu for investing in the biotechnology sector. These conditions… Read More »
AlphaProfit’s low risk, low effort investment strategy correctly picks up winners for every market environment. It enables AlphaProfit Premium Service Investment Newsletter and its model portfolios to consistently rank #1 in Hulbert Financial Digest.
Receive Free Reports
Sign up for the FREE investment newsletter AlphaProfit Money Matters and immediately receive Two Special Reports
Five Smart Ways to Profit from Sector Funds and ETFs
Avoid Three Common Mistakes ETF Investors Make
Don’t miss timely investment tips. Stay ahead of the market with AlphaProfit MoneyMatters in your inbox
Premium Service Performance
Model Portfolio Annualized Returns
DEC. 1993 to DEC. 2022
Fidelity Agg. Growth
17.5%
Fidelity Growth
14.4%
ETF Agg. Growth
17.4%
ETF Growth
14.2%
No-Fee Growth (inc. 2009)
10.7%
S&P 500
9.6%
Stock Recommendation Returns
DEC. 2013 to DEC. 2022
Win Rate
91%
Avg. Holding Period
2.6 months
Avg. Gain
12.6%
MEET
DR. SAM SUBRAMANIAN
Sam Subramanian PhD, MBA has credentials that are the envy of most investment advisers. He combines strong quantitative skills with deep financial expertise and insights on inner workings of Wall Street and corporations. His creativity has helped him win 16 U. S. patents.
Prior to founding AlphaProfit Investments, LLC, Sam worked in positions of increasing responsibility in Finance and Corporate Strategy for McKinsey & Company, Exxon Corporation, and Unocal Corporation. His work centered on Acquisitions and Divestitures, Asset Valuation, Trading, Bankruptcies, and Risk Management.
Well aware of the dismal returns produced by money managers, he was determined to take charge of his own investments. He created a low cost, low effort but high return investing system and rigorously tested it for over two decades using his own money.
This high-performance system helped Sam to quickly become financially independent. Sam still invests his money, using the now award-winning system he created. He shares the unbiased, crystal-clear recommendations and market moves with his subscribers.
The AlphaProfit ETF style rotation model portfolio will be reconstituted with new recommendations on Monday, November 20. Learn more about AlphaProfit's Free and Premium Service investment newsletters.
DEC. 1993 to DEC. 2022
